Merck rival Summit draws new buy from Truist on deal prospects
Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won ...
Merck & Co. Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
BioSpace4h
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Merck downgraded to Hold from Buy at Truist
Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 ...
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Brattleboro Reformer1d
Natural wonders: Finding the 'magic of winter' at Merck Forest
Serenity may feel hard to come by these days, but the natural world still offers solace for those willing to seek it.
Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...